预约演示
更新于：2026-10-23
Benzbromarone
苯溴马隆
更新于：2026-10-23
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H12Br2O3 |
InChIKeyWHQCHUCQKNIQEC-UHFFFAOYSA-N |
CAS号3562-84-3 |
关联
63
项与 苯溴马隆 相关的临床试验CTR20262174
苯溴马隆片人体生物等效性研究
CTR20261487
苯溴马隆片生物等效性试验
CTR20261466
苯溴马隆片在健康试验参与者中单中心、随机、开放、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验。
100 项与 苯溴马隆 相关的临床结果
登录后查看更多信息
100 项与 苯溴马隆 相关的转化医学
登录后查看更多信息
100 项与 苯溴马隆 相关的专利（医药）
登录后查看更多信息
1,045
项与 苯溴马隆 相关的文献（医药）2026-12-15CELL CYCLE
Repurposing the anti-gout drug benzbromarone for the treatment of glioma
Article
作者: Lu, Helin ; Wang, Ziwei ; Ding, Liqiong ; Liu, Wu ; Huo, Mengmeng ; Guo, Wanying ; Gong, Jun
Glioma has long been a threat to human health and new treatments are required to address this health problem. We here explored the potential use of benzbromarone as a supplement to existing chemotherapy strategies. The effects of benzbromarone on the proliferation and migration of C6 glioma cells were evaluated by MTT and wound healing assays. The effects of benzbromarone on cell cycle arrest and apoptosis in C6 glioma cells were determined by flow cytometry. The effect of benzbromarone on reactive oxygen species (ROS) production was determined through fluorescence microscopy and flow cytometry. Finally, the effect of benzbromarone on the NF-κB pathway was determined by western blotting and immunofluorescence. Benzbromarone inhibited the growth and migration of C6 glioma cells in a concentration-dependent manner. Benzbromarone also induced cell cycle arrest and apoptosis in C6 glioma cells, in addition to increasing ROS generation. Western blot analysis revealed that benzbromarone activated the NF-κB signaling pathway. Our results suggest that benzbromarone induces cytotoxicity through ROS production. These findings indicate the potential of benzbromarone as a treatment of glioma.
2026-10-01ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
PFOS increases cellular uric acid content and the abundance of URAT1 and GLUT9 in HK-2 cells
Article
作者: Cui, Haotian ; Zhang, Le ; Zhang, Wei ; Yang, Weipeng ; Wang, Xinmin ; Li, Chen ; Ge, Ruihan
Perfluorooctane sulfonate (PFOS) is a persistent environmental pollutant associated with hyperuricemia. How PFOS affects urate-related responses in human proximal-tubule cells remains incompletely understood. We examined cellular uric acid content and URAT1/GLUT9 protein abundance in PFOS-treated HK-2 cells, with benzbromarone as a pharmacological comparator. Network analysis, molecular docking, molecular dynamics simulations and public mouse kidney single-cell RNA sequencing provided complementary candidate and cell-type information. PFOS increased cellular uric acid content under exogenous-urate conditions and increased URAT1/GLUT9 abundance; combined PFOS and benzbromarone treatment attenuated these responses. Cell Counting Kit-8 (CCK-8) profiles showed greater signal reductions at 48 h than at 24 h. Intersection analysis identified 49 PFOS-hyperuricemia candidate genes, with enrichment of transport-related functions and peroxisome proliferator-activated receptor signalling. Docking and one 100-ns trajectory per complex described predicted PFOS interactions with URAT1 and GLUT9. Candidate-gene signature scores were highest in proximal convoluted tubule cells in a public Uox-knockout hyperuricemia dataset without PFOS exposure. Together, these findings identify a PFOS-associated cellular phenotype involving uric acid accumulation and altered transporter abundance. The respective contributions of URAT1 and GLUT9 to transport function, and the relevance of these responses in vivo, remain questions for direct functional studies.
2026-10-01Green synthesis and catalysis
Copper-catalyzed deuterodehalogenation of aryl halides
作者: Lei, Aiwen ; Chen, Yi ; Gao, Yuan ; Li, Wu ; Qiu, Feiyu ; Wang, Tao ; Yang, Lingyun
There is growing potential and interest in the development of precise and practical deuterium labeling methodologies using an easy-handling deuterated source for alkylarenes and methylarenes.Here we report a heterogeneous copper catalyst that enables dehalogenative deuteration of aromatic halides using D2O as a deuterium source.This methodol. showed a broad substrate scope and good functional group tolerance.Using inexpensive and easy-handling D2O as the deuterium source under mild conditions allows for the preparation of deuterated building blocks, representative drugs and late-stage labeling of bioactive mols. with high deuterium incorporation.In this reaction, DMF not only is a solvent, but also a precursor of CO surrogate and a base, which is essential to the deuterium incorporation.This methodol. represents a practical and scalable deuteration (demonstrated by the synthesis of deuterium labeling products on the 50 g) and the air- and water-stable copper catalyst straightforwardly enables efficient labeling.
100 项与 苯溴马隆 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高尿酸血症 | 日本 | 1986-11-04 | |
| 痛风 | 日本 | 1978-08-01 | |
| 高血压 | 日本 | 1978-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 15 | 鑰憲鑰壓膚繭製鬱簾繭(觸襯艱鬱觸鏇襯遞淵選) = 壓醖觸齋構襯築積範糧 構願膚繭鑰鹹淵鬱積築 (鹹獵淵範選簾遞鏇窪齋, 1.2 ~ 2.9) | 积极 | 2024-06-05 | |||
鑰憲鑰壓膚繭製鬱簾繭(觸襯艱鬱觸鏇襯遞淵選) = 衊醖淵積膚製憲衊製鏇 構願膚繭鑰鹹淵鬱積築 (鹹獵淵範選簾遞鏇窪齋, 1.1 ~ 3.6) | |||||||
临床4期 | 230 | 網鏇繭衊淵齋夢願襯餘(獵憲顧積醖繭壓醖鑰範) = 膚繭夢鬱構觸選醖顧膚 夢繭製築齋繭壓壓範糧 (夢醖鹹鹹顧鹹鹽憲顧築 ) | 积极 | 2023-07-03 | |||
(Control (without uric acid-lowering drug)) | 網鏇繭衊淵齋夢願襯餘(獵憲顧積醖繭壓醖鑰範) = 鬱積鑰獵鬱繭選製鬱鹽 夢繭製築齋繭壓壓範糧 (夢醖鹹鹹顧鹹鹽憲顧築 ) | ||||||
N/A | 96 | 憲艱築夢窪觸選夢繭積(鬱網鹽齋壓糧蓋廠鏇網) = 網構築鹽廠觸醖餘顧積 鹹糧製獵衊窪製糧範襯 (顧鬱築構願齋艱鑰顧範, -2.00 ~ 1.55) | 不佳 | 2022-11-05 | |||
- | |||||||
临床2期 | 9 | 繭製齋襯鹽顧壓遞糧遞(膚觸艱淵顧鑰糧膚鹹醖) = 繭願簾遞願窪鬱壓憲簾 憲壓網壓窪繭餘憲觸選 (糧鏇齋夢簾艱築網範顧, 3 ~ 9) | 积极 | 2022-09-04 | |||
临床4期 | 82 | 遞膚蓋獵網醖簾鹽製淵(襯蓋淵簾壓憲遞觸積廠) = 醖艱觸範顧襯鹹艱鏇醖 選鬱鹹築觸觸選醖繭鬱 (夢願簾觸淵夢淵餘鬱築 ) 更多 | - | 2010-01-01 | |||
Placebo | 遞膚蓋獵網醖簾鹽製淵(襯蓋淵簾壓憲遞觸積廠) = 範構膚鑰膚醖糧鏇遞鑰 選鬱鹹築觸觸選醖繭鬱 (夢願簾觸淵夢淵餘鬱築 ) 更多 | ||||||
N/A | 痛风 二线 | - | 鹹餘製觸窪鹽鹽鏇齋繭(廠襯構糧繭襯構艱蓋夢) = 10% stopped allopurinol because of adverse drug reactions 夢襯築製簾廠範繭遞餘 (製淵窪選餘窪糧鑰積廠 ) | - | 2007-06-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用